RNAZ (TransCode Therapeutics, Inc. Common Stock) Stock Analysis - News
TransCode Therapeutics, Inc. Common Stock (RNAZ) is a publicly traded Healthcare sector company. As of May 21, 2026, RNAZ trades at $6.35 with a market cap of $5.66M and a P/E ratio of -0.12. RNAZ moved +0.00% today. Year to date, RNAZ is -17.43%; over the trailing twelve months it is -25.12%. Its 52-week range spans $5.56 to $739.20. Rallies surfaces RNAZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in RNAZ news today?
TransCode Names Dr. Anna Moore SAB Chair, Signs MSU Research Deal: TransCode Therapeutics has appointed co-founder Anna Moore, PhD, as Chair of its Scientific Advisory Board to guide its RNA-based cancer therapy research. The company signed a sponsored research agreement with Michigan State University to accelerate development and combination studies of its lead candidate TTX-MC138 with Seviprotimut-L and standard therapies.
Fitzgerald Thomas A bought 49.35K (~$25.17K) on Sep 28, 2023.
Dudley Robert Michael bought 98.00K (~$49.98K) on Sep 28, 2023.
Dudley Robert Michael bought 12.00K (~$31.82K) on Jun 21, 2023.
RNAZ Analyst Consensus
RNAZ analyst coverage data. Average price target: $0.00.
Common questions about RNAZ
What changed in RNAZ news today?
TransCode Names Dr. Anna Moore SAB Chair, Signs MSU Research Deal: TransCode Therapeutics has appointed co-founder Anna Moore, PhD, as Chair of its Scientific Advisory Board to guide its RNA-based cancer therapy research. The company signed a sponsored research agreement with Michigan State University to accelerate development and combination studies of its lead candidate TTX-MC138 with Seviprotimut-L and standard therapies.
Does Rallies summarize RNAZ news?
Yes. Rallies summarizes RNAZ news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is RNAZ research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RNAZ. It does not provide personalized investment advice.
